Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non Operating Income (2017 - 2025)

X4 Pharmaceuticals filings provide 8 years of Other Non Operating Income readings, the most recent being -$676000.0 for Q3 2025.

  • On a quarterly basis, Other Non Operating Income fell 399.12% to -$676000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 76.26% increase, with the full-year FY2025 number at -$753000.0, down 139.06% from a year prior.
  • Other Non Operating Income hit -$676000.0 in Q3 2025 for X4 Pharmaceuticals, down from $2.6 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $25.2 million in Q3 2023 to a low of -$3.8 million in Q4 2022.
  • Median Other Non Operating Income over the past 5 years was $105000.0 (2024), compared with a mean of $1.3 million.
  • Biggest five-year swings in Other Non Operating Income: crashed 495.95% in 2022 and later soared 5806.12% in 2023.
  • X4 Pharmaceuticals' Other Non Operating Income stood at -$689000.0 in 2021, then plummeted by 445.28% to -$3.8 million in 2022, then skyrocketed by 94.97% to -$189000.0 in 2023, then surged by 470.37% to $700000.0 in 2024, then crashed by 196.57% to -$676000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$676000.0 (Q3 2025), $2.6 million (Q2 2025), and $105000.0 (Q1 2025) per Business Quant data.